Table 3.
On‐study adverse events (n = 18)
| Adverse event | All cycles | ||||
|---|---|---|---|---|---|
| Grade 1 No. (%) | Grade 2 No. (%) | Grade 3 No. (%) | Grade 4 No. (%) | Grade 5 No. (%) | |
| Anemia | 1 (5.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| WBC decrease | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Neutrophil decrease | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Platelet decrease | 2 (11.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| AST increase | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| ALT increase | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| ALP increase | 1 (5.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Skin rash | 1 (5.5) | 1 (5.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; WBC, white blood cell.